Vedanta bets on captive bauxite amid pricing dispute with Odisha Mining Corp
Vedanta made an announcement for FY28.
· LiveMint Companies
The company received a long-pending consent to operate its Sijimali bauxite mine in Odisha in September and now plans to begin production this financial year itself, targeting 1 million tonnes of output. The production is expected to rise to 5-6 million tonnes in FY28.
Key facts
- Period
- FY28
The analysis
Against that, the stock is +0.1% on the day at ₹262.00, and has returned -6.0% over three months. It sits 26% below its 52-week high, which means a good deal of bad news was already in the price. The metals & mining sector has moved -7.1% over the same period, so Vedanta is running 1.1 points ahead of its peers.
For Vedanta, the question is how much of this is already reflected in the price and how much re-rates the metals & mining peer set alongside it.
Market context
- In focus: Vedanta (VEDL), in Metals & Mining.
- Over three months: Vedanta -6.0% against Metals & Mining -7.1% (1.1 points ahead).
- At least 25% below the 52-week high: Vedanta (26%).
- Vedanta: 52-week and period figures are measured from 30 Apr 2026, when its price was reset by a corporate action (such as a demerger or split).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| VedantaVEDL · Metals & Mining · Price reset 30 Apr 2026 | ₹262.00 | +0.1% | -0.8% | -6.0% | -26.1% | 0.9× | — |
Metals & Mining
1M +0.6% · 3M -7.1%
Vedanta
Financial Services
1M +1.9% · 3M -8.6%
Prices as of 9 Nov 2026, 16:11 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
Coal India, IOCL, Vedanta to BPCL: What dividends mean for the Indian stock market amid bull trend buzz? Experts decode
Anthropic Consults Vedanta Monk Swami Sarvapriyananda On AI Ethics, Consciousness And Alignment
MakeMyTrip's India subsidiary receives Sebi approval to float IPO
Ashok Leyland, Paytm down after 6-day rally; analyst flags positive charts
Big relief for cancer patients: Prices of 1,364 medicines cut, savings estimated at ₹3,540 crore annually